15

May2019

Status Summary Of Innovative Medicine pCPA Negotiations As Of April 30, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. In Table 1 below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. PDCI Target Insights (since last pCPA ... Read More

14

Mar2019

Status Summary of Innovative Medicine pCPA Negotiations as of February 28, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. In Table 1 below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest.... Read More

15

Feb2019

Status Summary of Innovative Medicine pCPA Negotiations as of January 31, 2019

The Office of the pan-Canadian Pharmaceutical Alliance (pCPA) assesses brand name drug products for public funding either collectively or individually at the provincial and territorial levels. Each month the pCPA issues an update on the previous month’s negotiation activity. A file is complete once a Letter of Intent (LOI) is ... Read More

17

Jan2019

Status Summary of Negotiations on Brand Name Drugs as of December 31, 2018

The Office of the pan-Canadian Pharmaceutical Alliance (pCPA) assesses brand name drug products for public funding either collectively or individually at the provincial and territorial levels. Each month the pCPA issues an update on the previous month’s negotiation activity. A file is complete once a Letter of Intent (LOI) is ... Read More

20

Dec2018

CADTH Releases Pharmaceutical Review Update Issue 4

New updates from pCODR are as follows: Webinar on Clinician Input and Feedback Seminar CADTH is hosting a webinar in collaboration with Innovation Medicines Canada (IMC) on January 22nd, 12:00 pm to 1:00 pm EST, to provide detailed information about this process and new tools being offered for clinicians. This webinar ... Read More

14

Jun2018

pCPA Releases its Brand Process Guidelines

On June 13, 2018, after considerable time in development, the pCPA released its Brand Process Guidelines for external feedback. The pCPA is interested in receiving feedback from all sectors with a stake in the negotiation process: brand and generic pharmaceutical companies, patient organizations, and other interested parties. The guidance documents, which ... Read More

04

May2018

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30th, 2018:  46 negotiations are currently underway with 7 new files added since the last update of March 31st, 2018: Adlyxine (lixisenatide): Used to treat type 2 diabetes mellitus Ilaris (canakinumab): Used ... Read More

12

Apr2018

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2018: 40 negotiations are currently underway with 4 new files added since the last update of February 28, 2018: Darzalex (daratumumab): Used to treat multiple myeloma Fiasp (insulin aspart): Used to ... Read More

29

Mar2018

Reminder: New prices for generics under pCPA/CGPA agreement become effective April 1st, 2018

Reminder: New prices for generics under pCPA/CGPA agreement become effective April 1st, 2018 In January 2018, the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) announced a five-year agreement that will reduce drug prices for all Canadians who use prescription generic drugs, participating public drug plans, and employee ... Read More

08

Feb2018

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of January 31, 2018: 35 negotiations are currently underway with 2 new files added since the last update of December 31, 2017: Spinraza (nusinersen): Used to treat 5q Spinal Muscular Atrophy Victoza (liraglutide): Used ... Read More